Live tape
Top 8, mentions 7d14,334NVDA4,850 mentions▲ +0.04GOOGL2,061 mentions▲ +0.04SPY1,736 mentions▲ +0.06QQQ1,554 mentions▲ +0.05AMD1,212 mentions▲ +0.08SPCX1,106 mentions▲ +0.05TSLA954 mentions▲ +0.04SNDK861 mentions▲ +0.05

Equity · Healthcare

ORIC

NASDAQ

ORIC Pharmaceuticals (ORIC)

10.73 USD −0.05% vs prior close
ORIC Pharmaceuticals, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.

Track this symbol on TradingView
Market cap
1.1B USD
EPS, diluted, year to Dec 2025
−1.47 USD
52-week range
7 USD – 14.27 USD
Avg volume
397.6K

as of Jul 17, 2026

Have ORIC Pharmaceuticals (ORIC) insiders bought or sold shares recently?

In the 90 days to 10 Nov 2026, ORIC Pharmaceuticals insiders reported 5 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 6 Oct 2025, show no open-market purchase.

Form 4, 90 days to 10 Nov 2026, newest reported trade 20 Oct 2026

0buys
5sells
$1.52Mnet sold
5other filings
Have ORIC Pharmaceuticals (ORIC) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
20 Oct 2026Piscitelli DominicChief Financial OfficerSell14,000189K USD
01 Oct 2026Heyman Richard A.DirectorSell6,70087K USD
28 Sep 2026Piscitelli DominicChief Financial OfficerSell13,400181K USD
24 Sep 2026Piscitelli DominicChief Financial OfficerSell6008K USD
26 Aug 2026Piscitelli DominicChief Financial OfficerSell77,0001.1M USD
Sold5 open-market sales111,700$1.52M
5 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have ORIC Pharmaceuticals (ORIC) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
20 Oct 2026Piscitelli DominicChief Financial OfficerOption exercise14,00061K USD
01 Oct 2026Heyman Richard A.DirectorOption exercise3,5006K USD
28 Sep 2026Piscitelli DominicChief Financial OfficerOption exercise13,40058K USD
24 Sep 2026Piscitelli DominicChief Financial OfficerOption exercise6003K USD
26 Aug 2026Piscitelli DominicChief Financial OfficerOption exercise77,000377K USD

Which funds hold ORIC Pharmaceuticals (ORIC)?

8 of the 45 institutional funds we track reported a ORIC Pharmaceuticals position for the quarter ended 30 Jun 2026 — a combined 119.4M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold ORIC Pharmaceuticals (ORIC)?
FundPositionSharesValueShares q/q
Viking Global InvestorsHeld (±25%)5,126,76255.5M USD−12.0%
Citadel AdvisorsHeld (±25%)2,595,29928.1M USD+7.1%
D. E. Shaw & Co.Added1,580,21617.1M USD+3,459.8%
Millennium ManagementAdded697,6947.6M USD+1,951.3%
Two Sigma InvestmentsNew position603,6646.5M USD
AQR Capital ManagementAdded358,7513.9M USD+110.9%
Tudor Investment CorpAdded42,409459K USD+25.9%
Balyasny Asset ManagementTrimmed24,201262K USD−95.4%

What has been filed or recorded for ORIC Pharmaceuticals (ORIC)?

The filings we hold for ORIC Pharmaceuticals, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 13 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for ORIC Pharmaceuticals (ORIC)?
And
13 Oct 2026Fails to deliverShares failed to deliver60,077 shares710K USD notional · 0.058% of shares out
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.38 USD
30 Jun 2026FinancialsTotal assets404.7M USDat period end
30 Jun 2026FinancialsTotal equity381.3M USDat period end
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.34 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −1.47 USD
31 Dec 2025FinancialsNet income−129.5M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−1.47 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.33 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.47 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.42 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −1.83 USD
30 Sep 2024Quarterly earningsQ3 2024 reportedEPS −0.49 USD

What do people ask about ORIC Pharmaceuticals (ORIC)?

From live data
What is ORIC Pharmaceuticals’ market cap?1.1B

ORIC Pharmaceuticals is worth 1.1B USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

Have ORIC Pharmaceuticals insiders bought or sold shares recently?5 sales

In the 90 days to 10 Nov 2026, ORIC Pharmaceuticals insiders reported 5 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 6 Oct 2025, show no open-market purchase. A further 5 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

Which funds own ORIC Pharmaceuticals?8 of 45

8 of the 45 funds we track reported a ORIC Pharmaceuticals position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Viking Global Investors, Citadel Advisors and D. E. Shaw & Co. See Funds

When did ORIC Pharmaceuticals last report earnings?−0.38

ORIC Pharmaceuticals last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −0.38 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings